Have a feature idea you'd love to see implemented?
Let us know!
CMMB Chemomab Therapeutics Ltd
Price (delayed)
$1.44
Market cap
$20.68M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.1
Enterprise value
$15.93M
Chemomab is a clinical-stage biotech company focusing on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need. Based on the unique and pivotal role of
Highlights
CMMB's EPS has surged by 63% year-on-year and by 29% since the previous quarter
CMMB's net income has surged by 55% year-on-year and by 22% since the previous quarter
The debt has soared by 155% YoY but it is down by 8% QoQ
CMMB's equity has plunged by 55% YoY and by 25% from the previous quarter
CMMB's quick ratio is down by 23% YoY and by 19% from the previous quarter
Key stats
What are the main financial stats of CMMB
Market
Valuations
Earnings
Shares outstanding
14.36M
Market cap
$20.68M
Enterprise value
$15.93M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.05
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$15.05M
EBITDA
-$14.99M
Free cash flow
-$16.13M
Per share
Balance sheet
Liquidity
EPS
-$1.1
Free cash flow per share
-$1.13
Book value per share
$0.7
Revenue per share
$0
TBVPS
$1.02
Total assets
$14.54M
Total liabilities
$4.56M
Debt
$360,000
Equity
$9.99M
Working capital
$9.15M
Debt to equity
0.04
Current ratio
3.12
Quick ratio
3.12
Net debt/EBITDA
0.32
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-76.8%
Return on equity
-102.8%
Return on invested capital
-188.1%
Return on capital employed
-147%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CMMB stock price
How has the Chemomab Therapeutics stock price performed over time
Intraday
-7.1%
1 week
12.5%
1 month
-8.28%
1 year
75.61%
YTD
182.35%
QTD
-8.28%
Financial performance
How have Chemomab Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$16.03M
Net income
-$15M
Gross margin
N/A
Net margin
N/A
CMMB's net income has surged by 55% year-on-year and by 22% since the previous quarter
Chemomab Therapeutics's operating income has soared by 53% YoY and by 22% from the previous quarter
Growth
What is Chemomab Therapeutics's growth rate over time
Valuation
What is Chemomab Therapeutics stock price valuation
P/E
N/A
P/B
2.05
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
CMMB's EPS has surged by 63% year-on-year and by 29% since the previous quarter
CMMB's price to book (P/B) is 156% more than its last 4 quarters average of 0.8 and 105% more than its 5-year quarterly average of 1.0
CMMB's equity has plunged by 55% YoY and by 25% from the previous quarter
Efficiency
How efficient is Chemomab Therapeutics business performance
Chemomab Therapeutics's return on invested capital has decreased by 9% YoY but it has increased by 7% QoQ
The return on assets has increased by 9% year-on-year and by 8% since the previous quarter
CMMB's return on equity is up by 6% since the previous quarter
Dividends
What is CMMB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CMMB.
Financial health
How did Chemomab Therapeutics financials performed over time
CMMB's total assets is down by 50% year-on-year and by 19% since the previous quarter
The total liabilities has declined by 34% year-on-year and by 2.5% since the previous quarter
The debt is 96% lower than the equity
The debt has soared by 155% YoY but it is down by 8% QoQ
CMMB's equity has plunged by 55% YoY and by 25% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.